Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/29/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK
6. S
7. GAP
8. DG
9. ULTA
10. NVDA

Go back to Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Novocure (NVCR) Climbs 70% After Pivotal LUNAR Study in NSCLC Met Primary Overall Survival Endpoint

January 5, 2023 7:10 AM EST

Novocure (NASDAQ: NVCR) Climbs 70% After Pivotal LUNAR Study in NSCLC Met Primary Overall Survival Endpoint

... More